Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Scott Antonia

Dr. Scott Antonia

Director, Cancer Immunotherapy

Medical oncologist Dr. Scott Antonia is director of the newly formed Center for Cancer Immunotherapy at the Duke Cancer Institute in Durham, North Carolina.

Get in touch
Jump to a Topic:

About Scott Antonia

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Team Leader icon

    Team Leader

  • 20+ Years of Experience icon

    20+ Years of Experience

  • Works for Specialty Center icon

    Works for Specialty Center

  • Immunotherapy icon


Since his appointment in February 2019, Antonia has focused on developing an elite immunotherapy program at Duke to better treat diseases such as lung cancer and malignant pleural mesothelioma.

Immunotherapy involves finding more effective ways to use a patient’s own immune system in the fight against cancer.

For years, Antonia has been recognized as a world leader and pioneer in the transition of cancer therapeutics.

Antonia joined Duke Cancer Institute after more than two decades at the Moffitt Cancer Center in Tampa, Florida, including the previous seven years as chairman of the Department of Thoracic Oncology.

Treating and Researching Mesothelioma

At Moffitt, Antonia spearheaded the creation of the Mesothelioma Research and Treatment Center, which focused on the rare and aggressive cancer caused by asbestos.

He was recognized as Physician of the Year in 2005, Mentor of the Year in 2008 and Researcher of the Year in 2018 at Moffitt.

Antonia was the lead author of a study published by the New England Journal of Medicine in 2019 that detailed the effectiveness of Imfinzi (durvalumab) when combined with chemotherapy to treat non-small cell lung cancer.

Another study in 2019 proved the effectiveness of Opdivo, also known as nivolumab, as a long-term benefit for lung cancer. Cure Today and Medscape both published the study.

“Our principle motivation is to develop new therapies for unresectable tumors,” Antonia said. “Cancer treatment in general looks more promising now than ever before, but we can’t stop now.”

As a clinician, Antonia also has been credited with developing better collaboration between the basic research scientists and the clinical researchers, accelerating therapeutic advances.

Immunotherapy Tumor Vaccines

At Moffitt, Antonia’s research program included novel T-cell therapies and tumor vaccines in combination with immunotherapy strategies.

He has vast experience in developing clinical trials that have consistently advanced cancer treatment.

Antonia earned a Ph.D. and his medical degree from the University of Connecticut. He completed a residency in internal medicine and a fellowship in medical oncology from Yale University.

He also received a post-doctoral fellowship in immunobiology from the Yale University School of Medicine.

His work with lung cancer played a role in developing guidelines adopted and published by the National Comprehensive Cancer Network.

Disclaimer: Dr. Scott Antonia has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Kahl, K. (2019, April 3). Pooled Analysis Shows Long-Term Benefit with Opdivo in Non-Small Cell Lung Cancer.
    Retrieved from:
  2. Duke Cancer Institute. (2019, February 22). Antonio Appointed Director of DCI Center for Cancer Immunotherapy.
    Retrieved from:
  3. Duke Cancer Institute. (n.d.). Antonia, Scott Joseph. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 9, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now